{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:55:10Z","timestamp":1791860110969,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI14\/00242"],"award-info":[{"award-number":["ICI14\/00242"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01321"],"award-info":[{"award-number":["PI16\/01321"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["INT15\/00112"],"award-info":[{"award-number":["INT15\/00112"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI17\/00233"],"award-info":[{"award-number":["FI17\/00233"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["754995"],"award-info":[{"award-number":["754995"]}]},{"name":"Biomarker-Driven Immunosuppression Minimization (BIODRIM) Consortium","award":["FP7\/2007\u20132013"],"award-info":[{"award-number":["FP7\/2007\u20132013"]}]},{"name":"Biomarker-Driven Immunosuppression Minimization (BIODRIM) Consortium","award":["SLT002\/16\/00183"],"award-info":[{"award-number":["SLT002\/16\/00183"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to establish guided preventive strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, interventional, multicenter clinical trial assessed the value of monitoring pretransplant CMV-specific cell-mediated immunity (CMI) using an interferon-\u03b3 release assay to predict CMV infection in kidney transplantation. One hundred sixty donor\/recipient CMV-seropositive (D+\/R+) patients, stratified by their baseline CMV (immediate-early protein 1)\u2013specific CMI risk, were randomized to receive either preemptive or 3-month antiviral prophylaxis. Also, 15-day posttransplant CMI risk stratification and CMI specific to the 65 kDa phosphoprotein (pp65) CMV antigen were investigated. Immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas 20% received thymoglobulin induction therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients at high risk for CMV based on pretransplant CMI developed significantly higher CMV infection rates than those deemed to be at low risk with both preemptive (73.3% vs 44.4%; odds ratio [OR], 3.44 [95% confidence interval {CI}, 1.30\u20139.08]) and prophylaxis (33.3% vs 4.1%; OR, 11.75 [95% CI, 2.31\u201359.71]) approaches. The predictive capacity for CMV-specific CMI was only found in basiliximab-treated patients for both preemptive and prophylaxis therapy. Fifteen-day CMI risk stratification better predicted CMV infection (81.3% vs 9.1%; OR, 43.33 [95% CI, 7.89\u2013237.96]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pretransplant CMV-specific CMI identifies D+\/R+ kidney recipients at high risk of developing CMV infection if not receiving T-cell\u2013depleting antibodies. Monitoring CMV-specific CMI soon after transplantation further defines the CMV infection prediction risk. Monitoring CMV-specific CMI may guide decision making regarding the type of CMV preventive strategy in kidney transplantation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02550639.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1209","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T12:06:45Z","timestamp":1576930005000},"page":"2375-2385","source":"Crossref","is-referenced-by-count":73,"title":["Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial"],"prefix":"10.1093","volume":"71","author":[{"given":"Marta","family":"Jarque","sequence":"first","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Crespo","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-3745","authenticated-orcid":false,"given":"Edoardo","family":"Melilli","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Hospital Miguel Servet , Zaragoza,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Moreso","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Vall d\u2019Hebr\u00f3n University Hospital, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Guirado","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Fundaci\u00f3 Puigvert , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Revuelta","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Hospital Cl\u00ednic de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montero","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Torras","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]},{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Riera","sequence":"additional","affiliation":[{"name":"Urology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Meneghini","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]},{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Taco","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manonelles","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Paul","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Hospital Miguel Servet , Zaragoza,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seron","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Vall d\u2019Hebr\u00f3n University Hospital, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Facundo","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Fundaci\u00f3 Puigvert , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]},{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Gil Vernet","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Griny\u00f3","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]},{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[{"name":"Experimental Nephrology Laboratory, Bellvitge Biomedical Research Institute, IDIBELL, Hospitalet de Llobregat ,","place":["Spain"]},{"name":"Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2024111411412571500_CIT0001","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"2024111411412571500_CIT0002","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","article-title":"The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients","volume":"2","author":"Sagedal","year":"2002","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"2024111411412571500_CIT0004","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.188.6.1047","article-title":"Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection","volume":"188","author":"Poli\u0107","year":"1998","journal-title":"J Exp Med"},{"key":"2024111411412571500_CIT0005","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1084\/jem.20052246","article-title":"Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation","volume":"203","author":"Casazza","year":"2006","journal-title":"J Exp Med"},{"key":"2024111411412571500_CIT0006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"2024111411412571500_CIT0007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2024111411412571500_CIT0008","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2024111411412571500_CIT0009","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0010","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/cid\/ciu589","article-title":"Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients","volume":"59","author":"L\u00facia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024111411412571500_CIT0011","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+\/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation"},{"key":"2024111411412571500_CIT0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411412571500_CIT0013","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0014","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0015","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/ajt.13684","article-title":"The \u201cABC\u201d of virus-specific T cell immunity in solid organ transplantation","volume":"16","author":"Sester","year":"2016","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0016","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411412571500_CIT0017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/tri.12318","article-title":"Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm","volume":"27","author":"L\u00facia","year":"2014","journal-title":"Transpl Int"},{"key":"2024111411412571500_CIT0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"2024111411412571500_CIT0019","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411412571500_CIT0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1600-6143.2008.02191.x","article-title":"Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation","volume":"8","author":"Mattes","year":"2008","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0021","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"key":"2024111411412571500_CIT0022","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0023","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-\u03b3 secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantis\u00e1n","year":"2013","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med"},{"key":"2024111411412571500_CIT0026","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiz194","article-title":"Different impact of rATG induction on CMV infection risk in D+R\u2013 and R+ KTRs","volume":"220","author":"Kaminski","year":"2019","journal-title":"J Infect Dis"},{"key":"2024111411412571500_CIT0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcv.2016.11.012","article-title":"Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients","volume":"87","author":"Jung","year":"2017","journal-title":"J Clin Virol"},{"key":"2024111411412571500_CIT0028","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/ajt.14672","article-title":"CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells","volume":"18","author":"Gatault","year":"2018","journal-title":"Am J Transplant"},{"key":"2024111411412571500_CIT0029","article-title":"Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant","author":"Kim","year":"2018","journal-title":"Korean J Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1209\/32522504\/ciz1209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2375\/34676671\/ciz1209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2375\/34676671\/ciz1209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:34:27Z","timestamp":1731587667000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/9\/2375\/5686894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1209","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,2,20]]}}}